Related Experiment Video

Updated: Nov 16, 2025

Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy
09:59

Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy

Published on: May 3, 2013

18.2K

Autophagy as a Vital Therapy Target for Renal Cell Carcinoma

Ying-Hua He1, Guo Tian2

  • 1Department of Clinical Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Frontiers in Pharmacology
|March 1, 2021
PubMed

Insights

Autophagy, a cellular recycling process, plays a complex role in renal cell carcinoma (RCC). This review explores how targeting autophagy offers potential new treatments for this cancer.

Area of Science:

  • Cellular Biology
  • Oncology
  • Biochemistry

Background:

  • Autophagy is a fundamental cellular process for degrading and recycling damaged components.
  • Autophagy exhibits dual roles in the development and progression of renal cell carcinoma (RCC).
  • Autophagy-related proteins are recognized as significant prognostic indicators in RCC patients.

Purpose of the Study:

  • To review the critical role of autophagy in renal cell carcinoma.
  • To explore the therapeutic potential of targeting autophagy for RCC treatment.

Main Methods:

  • Literature review of studies on autophagy in RCC.
  • Analysis of research on synthetic and phytochemical agents targeting autophagy.
  • Synthesis of current understanding of autophagy's function and therapeutic implications in RCC.

Main Results:

  • Autophagy has a complex, context-dependent role in RCC, influencing tumor initiation, growth, and response to therapy.
  • Several autophagy-related proteins serve as valuable biomarkers for predicting patient outcomes in RCC.
  • Targeting autophagy pathways presents a promising strategy for novel RCC therapies.

Conclusions:

  • Autophagy is a key player in RCC pathogenesis and progression.
  • Modulating autophagy holds significant therapeutic promise for renal cell carcinoma.
  • Further research into autophagy-targeting drugs is crucial for advancing RCC treatment options.
Keywords:
AMPK/mTORPI3K/AKT/mTORautophagyinducersinhibitorrcc

More Related Videos

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

1.2K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.0K

Related Concept Videos

Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Delivery Pathways to the Lysosome01:36

Delivery Pathways to the Lysosome

Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
8.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
3.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K